Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - VIROPHARMA INC | dex991.htm |
| EX-99.2 - PRESENTATION MATERIALS - VIROPHARMA INC | dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 11, 2010
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
| DELAWARE | 0-021699 | 23-2789550 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) | ||
| 730 STOCKTON DRIVE, EXTON, PENNSYLVANIA | 19341 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
(610) 458-7300
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
| Item 7.01. | Regulation FD Disclosure. |
On January 11, 2010, ViroPharma Incorporated (the “Company”), issued a press release commenting on 2009 Cinryze revenue guidance, providing 2010 revenue guidance for Cinryze and updating anticipated peak year sales for Cinryze. The full text of the press release is furnished as Exhibit 99.1 attached hereto.
In addition, the Company will present to various investors during the month of January 2010 including during the 28th Annual J.P. Morgan Healthcare Conference (the “Conference”). A copy of the presentation materials is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. This presentation will first be used on January 13, 2010 during an investor meeting.
| Item 9.01 | Financial Statements and Exhibits. |
The following exhibits are attached to this Form 8-K:
| (d) | Exhibit No. |
Description | ||
| 99.1 | Press release dated January 11, 2010. | |||
| 99.2 | Presentation materials to be presented to investors during the month of January 2010. | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VIROPHARMA INCORPORATED | ||||
| Date: January 11, 2010 | By: | /S/ J. PETER WOLF | ||
| J. Peter Wolf | ||||
| Vice President, General Counsel and Secretary | ||||
Index of Exhibits
| Exhibit |
Description | |
| 99.1 | Press release dated January 11, 2010. | |
| 99.2 | Presentation materials to be presented to investors during the month of January 2010. | |